DAK Scientific, Inc. is a medical device development company with a focus on designing products related to the Peripherally Inserted Central Catheter (PICC) market.
This medical device development company was founded by Deborah Kreatsoulas and Nicholas Kreatsoulas, DO in January 2017. Dr. Kreatsoulas worked as a Medical Director of Case Management in a community hospital where he managed patient flow throughout the hospital system. A problem continued to surface with admitted patients: What do you do with a IV drug user who has a PICC line? A typical PICC line patient can be discharged home to continue their therapy in an outpatient setting. However, the IV drug abuser or patient at risk for tampering with their PICC line ports cannot be and presents two problems: 1) they require constant monitoring which puts significant strain on hospital staff and 2) an unsecured PICC line port offers an easy opportunity to continue illicit drug use. The founders also discovered that there was a significant increase in infection rates, due to poor sterilization techniques by healthcare professionals at the PICC line injection ports.
The company’s goal is to provide a safe, secure, and successful experience for patients with PICC lines. PICC line insertions exceeded 2.9 million in 2015 and expect an annual growth rate of 8%. The total U.S. PICC line market was approximately $500 million in 2015.
In May 2017, DAK Scientific filed their first provisional patent defining the intellectual landscape of our product designs and is now entering a re-design phase, hoping to have a final product design with prototype modeling for product refinement in the next 6-9 months. The company is collaborating with Balance, Inc. of Cleveland, Ohio for our medical design prototype and product platforms.